FLEXI interactions with RNA-binding proteins. by Jun Yao (9646)

“…RNA-binding sites: I, within introns corresponding to FLEXIs; SS-I and SS-E, bimodally enriched across the 5’- and 3’ splice sites in unspliced pre-mRNAs with the midpoints in the intron or flanking exon (SS-I and SS-E, respectively; Figs <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1011416#pgen.1011416.g004" target="_blank">4A</a> and <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1011416#pgen.1011416.s011" target="_blank">S11</a>). mRNA levels, RBPs whose knockdown resulted in significant difference in mRNA levels (increased or decreased, DESeq2 |LFC|≥1, adjusted p≤0.05) from host gene of FLEXIs with a binding site for that RBP compared to those genes whose transcripts lacked a binding site for the same RBPs based on ENCODE RBP-knockdown datasets (p≤0.05 calculated by Fisher’s exact test; <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1011416#pgen.1011416.s013" target="_blank">S13 Fig</a>). …”

Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Data Sheet 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.pdf by figshare admin frontiersin (4545187)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Data Sheet 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.pdf by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Image 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Image 2_Restoring natural killer cell activity in lung injury with 1,25-hydroxy vitamin D3: a promising therapeutic approach.jpeg by Johnny Amer (495285)

“…BALF samples of ALI mice displayed high soluble PDL-1 and reduced soluble 1,25(OH)₂D levels compared to naïve mice. 1,25(OH)₂D treatment alongside OA led to a significant fourfold increase in the CD107a and NKp46 expressions to levels higher than the mice treated with the vehicle. …”

Image 3_Restoring natural killer cell activity in lung injury with 1,25-hydroxy vitamin D3: a promising therapeutic approach.jpeg by Johnny Amer (495285)

“…BALF samples of ALI mice displayed high soluble PDL-1 and reduced soluble 1,25(OH)₂D levels compared to naïve mice. 1,25(OH)₂D treatment alongside OA led to a significant fourfold increase in the CD107a and NKp46 expressions to levels higher than the mice treated with the vehicle. …”

Table 1_Restoring natural killer cell activity in lung injury with 1,25-hydroxy vitamin D3: a promising therapeutic approach.docx by Johnny Amer (495285)

“…BALF samples of ALI mice displayed high soluble PDL-1 and reduced soluble 1,25(OH)₂D levels compared to naïve mice. 1,25(OH)₂D treatment alongside OA led to a significant fourfold increase in the CD107a and NKp46 expressions to levels higher than the mice treated with the vehicle. …”

Image 1_Restoring natural killer cell activity in lung injury with 1,25-hydroxy vitamin D3: a promising therapeutic approach.jpg by Johnny Amer (495285)

“…BALF samples of ALI mice displayed high soluble PDL-1 and reduced soluble 1,25(OH)₂D levels compared to naïve mice. 1,25(OH)₂D treatment alongside OA led to a significant fourfold increase in the CD107a and NKp46 expressions to levels higher than the mice treated with the vehicle. …”

Table 1_Oxyresveratrol as a novel ferroptosis inducer exhibits anticancer activity against breast cancer via the EGFR/PI3K/AKT/GPX4 signalling axis.xlsx by Lei Xiang (528500)

“…Introduction<p>Oxyresveratrol (ORes) exhibits significant anticancer activity, particularly against breast cancer. …”

Data Sheet 1_Oxyresveratrol as a novel ferroptosis inducer exhibits anticancer activity against breast cancer via the EGFR/PI3K/AKT/GPX4 signalling axis.pdf by Lei Xiang (528500)

“…Introduction<p>Oxyresveratrol (ORes) exhibits significant anticancer activity, particularly against breast cancer. …”

Table_1_RvE1 Attenuates Polymicrobial Sepsis-Induced Cardiac Dysfunction and Enhances Bacterial Clearance.DOCX by Jianmin Chen (330051)

“…Here, we investigated whether the levels of SPMs are altered in the murine septic heart following polymicrobial sepsis-induced cardiac dysfunction. …”

Performance following comparative feedback by K. Skylar Powell (15384878)

“…The findings indicate that mixed comparative feedback is associated with decreased subsequent performance, whereas consistently negative feedback can be beneficial. …”

Data Sheet 1_LncRNA NRIR inhibits osteogenesis by promoting macrophage M1 polarization through RSAD2/NF-κB axis in peri-implantitis.pdf by Renshengjie Zhao (22459771)

“…However, our previous studies revealed significant upregulation of NRIR in peri-implantitis, suggesting its potential role in peri-implantitis. …”

Data_Sheet_1_Prognostic value of the Naples Prognostic Score in adult chronic obstructive pulmonary disease: NHANES 2005–2018.PDF by Yue Kang (427523)

“…A trend toward a decreasing prevalence of lung function indicators such as FEV1 [OR (95%CI), −339.70 (−456.53, −222.87)], FVC [OR (95%CI), −296.70 (−435.34, −158.06)], FEV1/FVC [OR (95%CI), −0.03 (−0.04, −0.02)], predicted FEV1 [OR (95%CI), −0.09 (−0.14, −0.04)], and predicted FVC [OR (95%CI), −0.08 (−0.15, −0.01)] was observed with increased NPS levels. …”

Image_1_Prognostic value of the Naples Prognostic Score in adult chronic obstructive pulmonary disease: NHANES 2005–2018.TIFF by Yue Kang (427523)

“…A trend toward a decreasing prevalence of lung function indicators such as FEV1 [OR (95%CI), −339.70 (−456.53, −222.87)], FVC [OR (95%CI), −296.70 (−435.34, −158.06)], FEV1/FVC [OR (95%CI), −0.03 (−0.04, −0.02)], predicted FEV1 [OR (95%CI), −0.09 (−0.14, −0.04)], and predicted FVC [OR (95%CI), −0.08 (−0.15, −0.01)] was observed with increased NPS levels. …”

Data Sheet 1_Therapeutic efficacy of a galactoglucan from Pleurotus citrinopileatus in constipation: modulation of aquaporin signaling and intestinal barrier.pdf by Yi Gao (112914)

“…The oral administration of PCP-g resulted in a significant reduction in constipation symptoms, as indicated by an increase in fecal water content, normalization of pellet formation, enhancement of total fecal mass, decreased latency to the first stool, and improved intestinal propulsion. …”